Oruka Therapeutics, Inc. has shared significant results from its Phase 2b EVERLAST-B clinical trial of ORKA-001, an investigational treatment for moderate-to-severe plaque psoriasis. This announcement, made on October 26, 2026, marks a pivotal moment for the company as it seeks to advance its product pipeline in the competitive pharmaceutical preparations sector.
The EVERLAST-B trial, which involved 187 patients, aimed to evaluate the safety and efficacy of ORKA-001, a half-life extended IL-23p19 monoclonal antibody. The trial's primary endpoint was the proportion of patients achieving PASI 100 at Week 16, and the results have shown promising efficacy.
Oruka Therapeutics, founded in Delaware and traded on Nasdaq under the ticker ORKA, specializes in developing innovative therapies for various diseases. The company's recent filing with the SEC (accession number 0001213900-26-112281) highlights its commitment to advancing treatments in the pharmaceutical industry.
According to the filing, the Week 16 results indicate that 61% of patients in the high-dose group achieved PASI 100, compared to 0% in the placebo group, with a statistically significant p-value of less than 0.0001. These findings suggest that ORKA-001 may offer a more effective treatment option for patients suffering from plaque psoriasis.
In addition to efficacy, the trial reported a favorable safety profile for ORKA-001. The company noted that at least one treatment-emergent adverse event was reported in 39% of patients receiving the 600 mg dose, which is comparable to 43% in the placebo group. Notably, no serious adverse events were linked to the treatment, indicating a promising safety profile.
Looking forward, Oruka plans to initiate Phase 3 trials for ORKA-001 in the first half of 2027, contingent on regulatory interactions. This step is critical as the company aims to solidify its position in the market and potentially bring ORKA-001 to patients in need.
Furthermore, Oruka's financial position remains robust, with cash, cash equivalents, and marketable securities totaling $1.1 billion as of June 30, 2026. This financial stability will support the company's ongoing operations and development efforts, including the anticipated Biologics License Application (BLA) filing for ORKA-001.
The positive results from the EVERLAST-B trial not only enhance Oruka's prospects but also reflect the growing interest in innovative treatments within the pharmaceutical preparations industry. Competitors in this space may need to reassess their strategies in light of Oruka's advancements.
As Oruka moves forward, it is expected to report additional clinical data, including 52-week results from the EVERLAST-A trial in December 2026 and Week 16 results from the ORKA-002 Phase 2 psoriasis trial in early 2027. These upcoming milestones will further shape the company's trajectory and its impact on the industry.
In conclusion, Oruka Therapeutics' announcement of positive Phase 2b trial results for ORKA-001 marks a significant step in its mission to provide effective treatments for psoriasis. With plans for Phase 3 trials on the horizon, the company is poised to make a meaningful impact in the pharmaceutical preparations sector.